JRC News

  1. 12 Jun 2012

    A picture is worth a thousand words. This is the reason why the image shown has been awarded the title of "image of the year" by the Society of Nuclear Medicine (SNM). It comes from a study led by the Joint Research Centre´s (JRC) Institute for Transuranium Elements (ITU) and conducted in collaboration with University Hospital Heidelberg

  2. 20 Jul 2011

    Experts from medicine, biology, chemistry and physics gathered in Berlin on 18 and 19 July for the 7th Symposium on Targeted Alpha Therapy, organised by the JRC's Institute for Transuranium Elements (ITU) and engineering company Eckert & Ziegler Eurotope GmbH.

  3. 13 Jan 2015

    The Institute for Transuranium Elements (JRC-ITU) of the European Commission, the Medical University Warsaw and Eckert & Ziegler Eurotope invite you to the 9th Symposium on Targeted Alpha Therapy.

  4. 27 Nov 2014

    How can research in food and diets address how we will live and eat in 2050? By supporting the move towards individualised diets; by ensuring the sustainability of the future food system; by improving our understanding of links between food, nutrients and health; and by focusing on integrated policy-making. These are the main findings of a new foresight report that will support work done under Horizon 2020, the EU's Funding Programme for Research and Innovation for 2014-2020.

  5. 14 Feb 2009

    Today at the annual meeting of the American Association for the Advancement of Science (AAAS) in Chicago, Ekaterina Dadachova of the Albert Einstein College of Medicine in New York gave a topical lecture on "Novel approaches to the therapy of infectious diseases", detailing the results of a joint project with scientists at the JRC Institute for Transuranium Elements (ITU) on the use of alpha-immunotherapy as a new option for the treatment of HIV infections.

  6. 16 Feb 2009

    Today at the annual meeting of the American Association for the Advancement of Science (AAAS) in Chicago, the JRC organised a scientific symposium on Pre-implantation genetic diagnosis (PGD), a service provided by in-vitro fertilisation (IVF) clinics to parents who want to avoid passing on genetic diseases to their children.

    PGD entails carrying out genetic tests on embryos in a laboratory to identify those that have a healthy version of a given gene. These embryos can then be safely implanted in a mother's womb. Not be confused with the more far-reaching and separate issue of actual genetic engineering with a view to creating 'designer babies', PGD enables fertilisation clinics to select embryos for implantation so that at-risk families can avoid passing on genetic disease to their children and to subsequent generations. Nevertheless, many questions continue to surround the technique.

    The JRC-organised symposium on PDF featured Dr Tarek El Toukhy from St Thomas' NHS Foundation Trust, London, Susannah Baruch from Johns Hopkins University, Baltimore and the JRC's own Dolores Ibarreta from the JRC Institute for Prospective Technological Studies (IPTS) in Seville. It was moderated by Karen Sermon from the Vrije Universiteit Brussel, Belgium.

    A lively debate with the audience followed the session.

    EU legislation requires that the Community establish high quality and safety standards for the use of blood, organs and other substances of human origin. A JRC report in late 2007 showed that guidelines were urgently needed on the counselling of patients that opt to screen their embryos created by in vitro fertilisation (IVF) for serious genetic disorders.

  7. 11 Dec 2013

    The European Commission has adopted the JRC's first Work Programme for 2014-2015 under Horizon 2020, the new EU strategy to boost research and innovation. The programme is aligned with the European Union's policy priorities, such as overcoming the economic crisis, encouraging the use of renewable energy and tackling climate change.

  8. 6 May 2011

    The JRC is hosting the Third International Conference on Alternatives for Developmental Neurotoxicity Testing (DNT3) on 10-13 May 2011 in Varese, Italy. The event brings together over 100 scientists and representatives from academia, industry and governmental organisations working on children's health, alternatives to animal testing and environmental protection.

  9. 29 Oct 2014

    A study evaluating the immunogenicity of tumour cells after they have been irradiated with the alpha particle emitter bismuth-213 (213Bi) showed resistance to further tumour challenge.

  10. 22 Mar 2013

    By measuring reference decay data for a suite of novel therapeutic nuclides (uranium -230, actinium-225, bismuth-213 and thorium-226) to be used in alpha-immunotherapy, the JRC has improved the accuracy of the doses received during cancer treatment.